Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421? excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421? is a trademark of Sirigen Group Ltd.

Additional reported applications (for the relevant formats) include: immunofluorescence⁴, blocking^6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections^{4, 11}. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

1. Maier H, et al. 2007. J. Immunol. 178:2714.
2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed

1. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
3. Wei H, et al. 2021. Malar J. 20:89. PubMed
4. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
5. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
6. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
7. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
8. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
9. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
10. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
11. Walsh SM, et al. 2021. eLife. 10:00. PubMed
12. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
13. Yu D, et al. 2019. Cell Commun Signal. 0.828472222. PubMed
14. Jiao S, et al. 2017. Clin Cancer Res. 23:3711. PubMed
15. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
16. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
17. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
18. van der Velden V, et al. 2017. J Immunol Methods. 10.1016/j.jim.2017.03.011. PubMed
19. Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed
20. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
21. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
22. Freed-Pastor WA, et al. 2021. Cancer Cell. :. PubMed
23. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
24. O'Reilly LA, et al. 2018. Immunity. 48:570. PubMed
25. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.